PharmaJet, Inc. announced that its needle-free intramuscular injection system, Stratis, has been selected to deliver Scancell Holdings plc’s iSCIB1+ DNA immunotherapy in a planned registrational Phase 3 trial for advanced melanoma, following promising Phase 2 data from the SCOPE study presented at the ESMO Immuno-Oncology Congress 2025. Delivered via Stratis, the therapy showed a 74 percent progression-free survival (PFS) rate at 16 months—substantially higher than typical outcomes with checkpoint inhibitors alone

What this platform-driven approach reveals about melanoma delivery constraints and DNA-based immunotherapies

This announcement marks a rare intersection between delivery innovation and oncology immunotherapy. For over a decade, the field has struggled to translate the immunological promise of plasmid DNA into clinically significant outcomes, with much of the friction rooted in suboptimal delivery techniques. The decision to pair iSCIB1+ with PharmaJet’s FDA-cleared needle-free injector suggests that developers are beginning to treat delivery as a core pillar of immunotherapy strategy, not an afterthought.

The Stratis system delivers intramuscular injections using a high-velocity fluid stream, eliminating the needle while ensuring reproducible tissue penetration. This approach offers a compelling alternative to electroporation, which has been widely used in DNA immunotherapy trials but remains painful, expensive, and operationally complex. Electroporation’s reliance on electrical pulses can deter enrollment and raise questions about feasibility in real-world settings. By contrast, Stratis offers a needle-free method that reduces pain, eliminates sharp waste, and improves throughput—features especially attractive in outpatient oncology clinics.

Importantly, DNA-based approaches rely on physical delivery methods that enable plasmid uptake into host cells for antigen expression. The traditional needle and syringe route often delivers DNA inconsistently into muscle or subcutaneous tissue, where degradation or poor transfection limits immune priming. PharmaJet’s platform is designed to standardize delivery at scale—a core enabler for DNA therapies moving toward commercialization.

Why this matters for delivery-device strategy in solid tumor immunotherapy

The Phase 2 SCOPE data reflects a broader trend: immunotherapies targeting solid tumors are beginning to adopt delivery co-strategies typically seen in infectious disease vaccine development. While therapeutic cancer vaccines have long faced skepticism due to weak T-cell priming and poor durability, Scancell’s iSCIB1+ leverages a proprietary ImmunoBody design to present engineered T-cell epitopes that may offer better CD8+ T-cell activation when delivered consistently.

Checkpoint inhibitors have set a high bar, but many patients still relapse or experience immune resistance. In this context, iSCIB1+ is not positioned as a standalone therapy but as an immune primer designed to enhance checkpoint efficacy. A needle-free co-delivery system allows for more predictable pharmacodynamics and potentially fewer injection-site complications—two variables that can make or break a multi-dose regimen in oncology.

The broader implication is that PharmaJet’s system may serve as a device-of-choice for next-generation oncology vaccines. Historically, only a handful of therapeutic cancer vaccines have reached commercial status, and nearly all rely on either electroporation or cumbersome intradermal delivery. If Stratis proves scalable, its adoption could extend to other nucleic acid-based platforms, including personalized neoantigen vaccines, synthetic long peptides, and mRNA constructs requiring high-fidelity muscle delivery.

What this changes for trial scalability, regulatory readiness, and investor visibility

The move toward Phase 3 with an already-cleared device is notable. Stratis holds 510(k) clearance from the U.S. Food and Drug Administration, CE marking in Europe, and WHO PQS certification. This dramatically reduces regulatory friction for Scancell as it designs its pivotal trial. Instead of managing parallel regulatory pathways for both drug and device, the company can integrate a validated delivery platform with known safety parameters, device lot traceability, and pre-cleared manufacturing protocols.

Clinicians following the field believe this dual advantage—clinical performance and regulatory simplicity—will be closely watched by others developing plasmid DNA therapies. Beyond regulatory ease, there is a clinical operations advantage. Unlike electroporation machines, which require extensive staff training and capital expense, Stratis devices can be used more flexibly across sites and geographies.

From an investor perspective, the commercial roadmap is gaining clarity. Scancell has indicated a potential market launch by 2029, contingent on Phase 3 success. Analysts will likely scrutinize not just the therapeutic data, but the operational viability of delivering DNA therapies at commercial scale through needle-free systems. PharmaJet, for its part, may see its platform elevated from a niche vaccine tool to a frontline oncology device—especially if real-world adoption improves trial efficiency, patient adherence, and clinical outcomes.

What risks and blind spots could disrupt this delivery-therapy combination in Phase 3

Despite the enthusiasm, the road to 2029 is fraught with known and unknown risks. The 74 percent PFS at 16 months is a promising result, but without a randomized comparator arm, the data cannot rule out selection bias, favorable patient phenotypes, or unmeasured confounders. While historical benchmarks provide context, regulatory agencies will demand superiority or non-inferiority trials with robust overall survival and quality-of-life endpoints.

There is also the risk of device integration fatigue. Oncology investigators are accustomed to well-understood injectable protocols, and even a simple switch to needle-free delivery could introduce variability if not seamlessly integrated into standard clinical workflows. While PharmaJet has a global distribution footprint, ensuring Stratis training, support, and uptime across dozens of sites will require significant investment.

From a competitive lens, the Phase 3 trial will enter an increasingly crowded space. Multiple checkpoint inhibitor combinations, including those involving bispecific antibodies, TCR therapies, and personalized mRNA vaccines, are all competing for the same patient cohorts. iSCIB1+ must not only demonstrate efficacy but offer a clear value proposition on durability, cost of goods, and patient experience.

There’s also a financial consideration: if device-enabled therapies are ultimately costlier than standard regimens, payers may balk unless quality-adjusted life years (QALYs) and health-economic models are strongly favorable. Regulatory watchers suggest that successful device-drug combinations will need to show not just clinical improvement but operational superiority—faster administration, fewer adverse events, and better patient throughput.

A wider lens: delivery platform convergence in cancer immunotherapy

This moment may represent a broader shift in oncology innovation strategy. Where therapeutic vaccines were once dismissed as ineffective, the confluence of delivery science, immune system insights, and device optimization is breathing new life into the modality. Much like the evolution of mRNA vaccines—where lipid nanoparticles became as critical as the mRNA payload—DNA vaccine success may hinge on the right co-platform.

PharmaJet is not alone in this space. Other players are exploring microneedle patches, gas-powered injectors, and skin-targeting technologies to overcome the limitations of traditional intramuscular administration. What sets Stratis apart is its off-the-shelf readiness and ability to deliver relatively large DNA volumes intramuscularly without requiring electricity or specialized infrastructure.

Clinicians and developers alike will be watching the Phase 3 trial closely—not just for efficacy data, but for operational feasibility, patient satisfaction, and site-level deployment fidelity. If PharmaJet and Scancell can prove that a delivery platform can change clinical trajectory without adding friction, the door may open for broader integration of device–drug combinations in oncology pipelines.

  advanced melanoma, DNA immunotherapy, drug delivery device, iSCIB1+, needle-free injection, oncology trials, PharmaJet, Scancell, SCOPE trial, Stratis